Open access · OA
via OpenAlex
Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals
Prashanthi Vemuri, David S. Knopman, Timothy G. Lesnick, Scott A. Przybelski, Michelle M. Mielke, Jonathan Graff‐Radford, Melissa Erin Murray, Rosebud O. Roberts, Maria E. Vassilaki, Val J. Lowe, Mary M. Machulda, David Thomas Jones, Ronald Carl Petersen, Clifford R. Jack
JAMA Neurology · 2017 · ▲ 140 citations
Abstract
Importance: While amyloid and neurodegeneration are viewed together as Alzheimer disease pathophysiology (ADP), the factors that influence amyloid and AD-pattern neurodegeneration may be considerably different. Protection from these ADP factors may be important for aging without significant ADP. Objective: To identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration in a population-based sample and to test the hypothesis that "exceptional agers" with advanced ages do not have significant ADP because they have protective factors for amyloid and neurodegeneration. Design, Setting, and Participants: This cohort study conducted a prospective analysis of 942 elderly individuals (70-≥90 years) with magnetic resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study of cognitive aging in Olmsted County, Minnesota. We operationalized "exceptional aging" without ADP by considering individuals 85 years or older to be without significant evidence of ADP. Main Outcomes and Measures: We evaluated predictors including demographics, APOE, intellectual enrichment, midlife risk factors (physical inactivity, obesity, smoking, diabetes, hypertension, and dyslipidemia), and the total number of late-life cardiac and metabolic conditions. We used multivariate linear regression models to identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration. Using a subsample of the cohort 85 years of age or older, we computed Cohen d-based effect size estimations to compare the quantitative strength of each predictor variable in their contribution with exceptional aging without ADP. Results: The study participants included 423 (45%) women and the average age of participants was 79.7 (5.9) years. Apart from demographics and the APOE genotype, only midlife dyslipidemia was associated with amyloid deposition. Obesity, smoking, diabetes, hypertension, and cardiac and metabolic conditions, but not intellectual enrichment, were associated with greater AD-pattern neurodegeneration. In the 85 years or older cohort, the Cohen d results showed small to moderate effects (effect sizes > 0.2) of several variables except job score and midlife hypertension in predicting exceptional aging without ADP. Conclusions and Relevance: The protective factors that influence amyloid and AD-pattern neurodegeneration are different. "Exceptional aging" without ADP may be possible with a greater number of protective factors across the lifespan but warrants further investigation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1001/jamaneurol.2017.0244
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Vemuri, P., Knopman, D.S., Lesnick, T.G., Przybelski, S.A., Mielke, M.M., Graff‐Radford, J., Murray, M.E., Roberts, R.O., Vassilaki, M.E., Lowe, V.J., Machulda, M.M., Jones, D.T., Petersen, R.C., & Jack, C.R. (2017). Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <em>JAMA Neurology</em>. https://doi.org/10.1001/jamaneurol.2017.0244
Vancouver
Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff‐Radford J, et al. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology. 2017. doi:10.1001/jamaneurol.2017.0244.
BibTeX
@article{prashanthi2017Evalua,
title = {Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals},
author = {Prashanthi Vemuri and David S. Knopman and Timothy G. Lesnick and Scott A. Przybelski and Michelle M. Mielke and Jonathan Graff‐Radford and Melissa Erin Murray and Rosebud O. Roberts and Maria E. Vassilaki and Val J. Lowe and Mary M. Machulda and David Thomas Jones and Ronald Carl Petersen and Clifford R. Jack},
journal = {JAMA Neurology},
year = {2017},
doi = {10.1001/jamaneurol.2017.0244},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Immunity & Ageing 2016
Open access · CC-BY
Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study
Brain 2023
Open access · CC-BY
The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
Alzheimer s Research & Therapy 2018
Open access · CC-BY
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Diabetes Care 2004
Open access · OA
Metabolic Syndrome as a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes
JAMA Neurology 2015
Preprint · OA
The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline: Exploring Interactions With Biomarkers of Alzheimer Disease
Annals of Internal Medicine 2023
Preprint · OA